AMP German Cannabis Group orders 150 kilograms of medical cannabis from Canadian Licensed Producer

– AMP German Cannabis Group Inc. (“AMP” or the “Company”) (FSE: C4T) (ISIN: CA00176G1028) (CSE: XCX) announces it has placed two orders for bulk and finished EU-GMP medical cannabis flower from a Canadian Licensed Producer (“Canadian LP”) of medical cannabis. AMP will be purchasing and importing to Germany, 50 kilograms of EU-GMP medical cannabis in September 2020 and a further 100 kilograms during January/February 2021. AMP and the Canadian LP plan to expand the supply agreement for monthly large volume purchases of medical cannabis as well as extracts. 

The Canadian LP operates an indoor growing and processing facility in Canada and was already EU-GMP certified by German authorities earlier this year.

Dr. Stefan Feuerstein, President of AMP, commented, “We are seeing a stronger than anticipated demand for medical cannabis in the German marketplace and Canada is one of a few credible suppliers to Germany in the short term. Demand from German pharmacies is so high that AMP will be adding pharmaceutical distributors across Germany that focuses solely on medical cannabis in the upcoming weeks. Our goal is to become a major importer to Germany by the end of 2021”

About AMP German Cannabis Group Inc.

AMP German Cannabis Group is licensed to import European Union – Good Manufacturing Practice (EU-GMP) medical cannabis and sell to pharmaceutical distributors or pharmacists directly, the only point-of-sale for medical cannabis to German patients. 

AMP has entered into a non-exclusive distribution agreement for medical cannabis with a leading distributor of pharmaceuticals products to more than 13,000 pharmacies throughout Germany for monthly shipments starting in the second half of 2020. 

For more information, please visit: www.amp-eu.com   

AMP social media links:

AMP Media Kit: www.amp-eu.com/media-kit

Neither the CSE nor its Regulation Services Provider (as that term is defined in the policies of the CSE) accepts responsibility for the adequacy or accuracy of this release.

This news release contains forward-looking statements that are based on the Company’s expectations, estimates and projections regarding its business and the economic environment in which it operates, including with respect to its business plans and milestones and the timing thereof. Although the Company believes the expectations expressed in such forward-looking statements are based on reasonable assumptions, such statements are not guarantees of future performance and involve risks and uncertainties that are difficult to control or predict. Therefore, actual outcomes and results may differ materially from those expressed in these forward-looking statements and readers should not place undue reliance on such statements. These forward-looking statements speak only as of the date on which they are made, and the Company undertakes no obligation to update them publicly to reflect new information or the occurrence of future events or circumstances unless otherwise required to do so by law.

SOURCE NEWSWIRE

All posts made on this website are provided for information purposes only. None of the information here is intended as investment advice, as an offer or solicitation of an offer to buy or sell, or as a recommendation, endorsement, or sponsorship of any security, Company, or fund. Before making an investment decision, you should seek the advice of a qualified and registered securities professional. Candlr is not receiving payment or commissions from companies for shared content on Candlr website unless its specified. View full disclaimer HERE.

Leave a Reply

This site uses Akismet to reduce spam. Learn how your comment data is processed.